Course Information

Melanoma – Recent advances in Immune-Checkpoint Inhibitors

Melanoma – Recent advances in Immune-Checkpoint Inhibitors

This module is intended for medical oncologists interested in the underlying research behind metastatic melanoma therapies and management of the most common associated treatment side-effects. Included within this 45 minute module are: summaries of landmark trials in the field of melanoma, associated published commentaries, and relevant case-based scenarios with response feedback.

Learning objectives:
  1. Review the outcomes of seminal publications and clinical trials that have led the changes in management for metastatic melanoma
  2. Anticipate the most common and serious side effects of Immune-Checkpoint Inhibitors
  3. Identify the best management options for side effects of melanoma therapy

This program was supported by educational grants from GlaxoSmithKline and Bristol-Myers Squibb.

Course Registration

Melanoma – Recent advances in Immune-Checkpoint Inhibitors

MDcme (on behalf of its consortium partners) protects the privacy of personal and other information regarding course registrants. MDcme will not release personally identifiable information to a third party without an individual's consent, except such information as is required for reporting purposes to the body or bodies accrediting this course for continuing education study credits. MDcme collects and reviews all course data (registration/course completion statistics, pre/post-test and satisfaction survey) to determine if a course meets participants' learning needs. Data is reviewed to improve existing courses and to inform the development of future course offerings. If an evaluation report is provided to a third party, all data is summarized, with no participant identifying information included. Given the importance and potential impact of some courses, evaluation data may be presented and/or published in academic venues. Again, this data is always summarized, with no identifying information included.

At times, a contributing/partner organization involved in a course may request individual participant data from pre/post or evaluation surveys for quality improvement or educational research purposes. This data would be de-identified so would not be associated with any personally identifiable information such as your name, profession, city, etc.

If requested by a contributing/partner organization:

Do you consent to the release of your individual, de-identified pre/post or evaluation survey data for the purposes of quality improvement or educational research?


You must have an account and be logged in to register for this course



Scientific Committee:

  • Dr. Kathryn Roth (Scientific Committee Chair), MD, FRCPC
    Assistant Professor, Department of Otolaryngology, Western University, London, ON
  • Dr. Scott Ernst, MD, FRCPC
    Division Head, Medical Oncology, Department of Oncology, Western University, London, ON
  • Dr. Alex Hammond, MD, BSC, MBBCH, ABRT, FRCPC
    Professor, Department of Oncology, Western University, London, ON
  • Michael Brock, MSc
    Educational Developer, Schulich School of Medicine & Dentistry, Western University, London, ON
  • Michael Murray, MSc
    Medical Writer, Schulich School of Medicine & Dentistry, Western University, London, ON